Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The program stands in direct contrast to the Starglo case above: where Starglo's geographic concentration became a liability during FDA review, PURPOSE 1's deliberate recruitment among the population most affected by the disease became a central part of the approval narrative, illustrating that disease-burden-aligned trial design can function as a scientific and regulatory asset rather than merely a compliance obligation
Nanoscale (2019) 11(13):6192205
Marketed by: Novo Nordisk Inc., Plainsboro, NJ 08536 For additional information about WEGOVY contact: Novo Nordisk Inc
10.1124/mol.111.074757 88 SecorJ
US$ 21.42
US$ 29.76
US$ 26.95
US$ 29.76
US$ 21.92
